India's
Ranbaxy gets final US FDA approval for cetirizine
hydrochloride tablets
Posted AtCNNMoney.com
MUMBAI, Dec. 31, 2007 (Thomson
Financial delivered by Newstex) -- India's Ranbaxy
Laboratories Ltd said it received final approval from
the US Food and Drug Administration (US FDA) to manufacture
and market allergic drug cetirizine hydrochloride
tablets in the US.
The company said the approval
is for over the counter sales of the tablets in strengths
of 5 mg and 10 mg.
In a filing with the Bombay
(OOTC:BBAO) Stock Exchange, Ranbaxy said cetirizine
tablets are the generic version of Pfizer Inc's (NYSE:PFE)
Zyrtec and used for temporary relief from runny nose,
sneezing, itching of the nose or throat, and itchy,
watery eyes due to hay fever or other upper respiratory
allergies.
The total annual market sales
for cetirizine hydrochloride tablets as a prescription
only product were 1.3 bln usd for the 12 months to
end-September, the company said.
Copyright Thomson Financial
News Limited 2007. All rights reserved.
The copying, republication
or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly
prohibited without the prior written consent of Thomson
Financial News.
December 31, 2007 |
